Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations (NCT05544552)
A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (SURF301)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic urothelial carcinoma of the bladder and urinary tract and other advanced solid tumors.
Who can join: Review the eligibility criteria below.
Location: Dana Farber Cancer Institute — Boston, Massachusetts
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- Dana Farber Cancer Institute — Boston, Massachusetts
- UMass Memorial Medical Center — Worchester, Massachusetts
- Memorial Sloan Kettering Cancer Center (MSKCC) — New York, New York
- Duke Cancer Institute (DCI) - Duke Cancer Center — Durham, North Carolina
- Cleveland Clinic - Main Campus — Cleveland, Ohio
- Vanderbilt University Medical Center (VUMC) - Vanderbilt-Ingram Cancer Center (VICC) - Nashville — Nashville, Tennessee
- Seattle Cancer Care Alliance (SCCA) - South Lake Union — Seattle, Washington
- Macquarie University — Macquarie Park, New South Wales
- Tasman Oncology — Southport, Queensland
- Princess Alexandra Hospital — Woolloongabba, Queensland
- Austin Health — Heidelberg, Victoria
- Peter MacCallum Cancer Research Unit — Melbourne, Victoria
- Linear Clinical Research Limited — Nedlands, Washington
- Institut de Cancerologie de L'Ouest (ICO) — Saint-Herblain,
- Institut Claudius Regaud, IUCT-Oncopole — Toulouse,
- Gustave Roussy (Institut de Cancerologie Gustave-Roussy) — Villejuif,
- NEXT Barcelona - Hospital Quironsalud Barcelona — Barcelona,
- Vall d'Hebron Institut d'Oncologia (VHIO) — Barcelona,
- NEXT Madrid - Hospital Universitario Quironsalud Madrid — Madrid,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Locally Advanced Urothelial Carcinoma
- Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma — Phoenix, Arizona
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer — Phoenix, Arizona
- Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma — New Haven, Connecticut
Explore by condition: All Locally Advanced Urothelial Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.